Biggest News Aggregation in the World
📰 Project Lucy News

Project Lucy News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Project Lucy. Real-time updates on events, politics, business and more.

7 Cheap Stocks to Buy That Are Priced in Single-Digit Territory

A final tip before we get into it. Since cheap stocks tend to move much more robustly than lower-priced fare, you don’t need to spend gobs of money to realize some incredible gains. Indeed, you’re better off just using “dumb money” for these ideas as the wild trading cuts both ways. Cheap Stocks to Buy: Sirius XM (SIRI) Source: Shutterstock Thanks to its vast library of content, Sirius XM represented a fan favorite for many worker bees prior to the pandemic. According to a Washington P...
United States William White Ammo Inc Washington Post Drug Administration Sirius Xm

Investigational New Drug Application

Shares of Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) hit a new 52-week low of $4.72 on Monday and was trading lower by more than 4 percent. Ariad Pharmaceuticals announced earlier in the day that the U.S. Food and Drug Administration has completed its review of the companys Investigational New... Read More... Dont Miss Any Updates! News Directly in Your Inbox Subscribe to:
Scopus Biopharma Inc Ariad Pharmaceuticals Drug Administration Ariad Pharmaceuticals Inc Diamedica Therapeutics Inc Investigational New Drug Application

Insider Cannabis Newsletter: May 21

Executive Moves Martha Stewart would become an official strategic advisor. Erik Knutson as CEO of cannabis beverage company Keef Brands. Tharp was previously president and COO, and Knutson will remain on the board.  Deals, launches, and IPOs Aurora Cannabis filed for a $300 million stock sale on Thursday. The filing mentions a possibility of a US acquisition, MarketWatch reports.  Cannabis SPAC Mercer Park Brand Acquisition Corp. said on Monday that it has upsized a previously announced equ...
United States University Of Mississippi City Of United Kingdom Kevin Carrillo Ron Wyden

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial News provided by Share this article MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication NEW YORK, May 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Companys clinical development...
United States Dan Karlin Rob Barrow Exchange Commission National Institute Of Mental Health Mindmed Finalizes Clinical Development

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Psychedelic Research Studies to Watch | Clinical Trials and More

INN takes a closer look at some of the biggest ongoing psychedelic research studies that could shape the future of the industry. The psychedelics investment proposition is an enticing one for investors, and the bedrock of the industry is the potential attached to clinical research on psychedelic substances. Thanks to the groundbreaking progress of studies and trials evaluating psychedelic treatments, the entire sector is gaining more attention as a new age of medicine becomes a very real possib...
City Of United Kingdom Robin Carhart Harris Rick Doblin Peter Thiel Psychedelics Research

Ceres Acquisition (CERAF), COMP SERVICES (CMPS), CURALEAF HLDGS INC by Curaleaf Hldgs Inc. (CURLF), MIND MEDICINE MINDMED by MIND MEDICINE MINDMED INC. (MMEDF), RED LIGHT HOLLAND CORP by Red Light Holland Corp. (TRUFF) - Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week

Horizons ETFs Made Waves When They Launched the World’s First Psychedelics Stock ETF on the NEO Exchange Early This Year The Dales Report sat down with Steve Hawkins, the President and CEO of Horizons ETFs for an interview, to learn a little bit more about the behind-the-scenes on creating a Psychedelics ETF like  Horizons Psychedelic Stock Index ETF (NEO: PSYK) from scratch, what investors should know, and where the Psychedelics industry – and others – might be headed. Right now, H...
City Of United Kingdom United States Canaccord Genuity Jenna Sobocan Raymond James

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience News provided by Share this article Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Office...
United States Robert Barrow Rob Barrow Robert Barrow Bio Development Officer Ohio State University

Up 1,130% in 2020, Is MindMed Still a Buy?

Author Bio Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Follow @alexcarchidi If youve ever struggled with anxiety, depression, addiction, or trauma, you know that securing your peace o...
Drug Administration Project Lucy Project Layla ப்ராஜெக்ட் லூசி ப்ராஜெக்ட் லேல
Source: fool.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science